|
|
|
| Changes of Serum Tumor Markers CEA, CA72-4 and CA153 in Patients with Postmenopausal Diabetes Mellitus |
| LI Hui-guang, GAO Gui-quan, GUO Min, et al |
| Department of Nuclear Medicine, Central Hospital of Tongchuan Mining Bureau, Shanxi 727000 |
|
|
|
|
Abstract 【Objective】To investigate the changes in serum tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen 72-4 (CA72-4) and CA153 in patients with postmenopausal type 2 diabetes mellitus (T2MD).【Methods】A total of 105 postmenopausal women with T2MD were selected as the observation group, and 94 healthy women of the same age were selected as the control group. The fasting plasma glucose (FPG), postprandial 2h blood glucose (2hPG), glycosylated hemoglobin A1c (HbA1c) and levels of CEA, CA72-4 and CA153 were compared between the two groups.【Results】The levels of FPG, 2hPG, HbA1c, CEA, CA72-4 and CA153 in the observation group were higher than those in control group, and the differences were statistically significant (P<0.05). Levels of CEA, CA72-4 and CA153 were lower in T2MD patients<65 years old than those patients ≥ 65 years old, and the difference was statistically significant (P<0.05). The CEA, CA72-4, and CA153 in HbA1c<7% T2MD patients were lower than those in HbA1c 7% ~ 9% and HbA1c>9% T2MD patients, and CEA, CA72-4 and CA153 levels were lower in T2MD patients with HbA1c of 7% ~ 9% than those with HbA1c>9%; the differences were statistically significant (P<0.05). The levels of serum CEA, CA72-4 and CA153 were positively correlated with FPB, 2hPG, HbA1c and age (P<0.05).【Conclusion】Compared to postmenopausal women with normal glucose metabolism, levels of serum CEA, CA72-4 and CA153 are higher in postmenopausal women with T2MD, which may be related to the fluctuation of blood glucose.
|
|
Received: 12 May 2017
|
|
|
|
|
|
[1] 杨梅,邓华聪.糖尿病与肿瘤关系研究进展[J].重庆医学,2013,42(6):700-702.
[2] 金建,叶菡洋.胰腺癌与糖尿病的相关性分析[J].中国基层医药,2010,17(21):3005-3006.
[3] Alberti KG,Zimmet PZ.Definition,diagnosis and classification of diabetes mellitus and its complications[J].Diabet Med,1998,15(7):539-553.
[4] 余娇娇,花芳,胡卓伟.糖尿病促进肿瘤发生发展的研究进展[J].药学学报,2016,51(7):1017-1024.
[5] 贾书冰.降糖药物对2型糖尿病患者肿瘤发病风险影响的网络Meta分析[J].沈阳药科大学学报,2016,33(4):326-333.
[6] 陈月红,杜亮,张春林,等.2型糖尿病对肿瘤发生风险的研究新进展[J].中华内分泌代谢杂志,2015,31(6):544-547.
[7] Bi Y,Lu J,Wang W,et al.Cohort profile:risk evaluation of cancers in Chinese diabetic individuals:a longitudinal (REACTION) study.[J].J Diabet,2014,6(2):147-157.
[8] 季林华,张斌,赵刚.75岁以上高龄胃癌患者临床特征分析[J].医学临床研究,2016,33(11):2273-2275.
[9] 刘超,杜万红,郑桃林.脂联素与老年2型糖尿病患者相关性研究[J].湖南师范大学学报(医学版),2012,9(3):42-44. |
|
|
|
2018, Vol. 35 
